质量改进干预对急性缺血性卒中及短暂性脑缺血发作患者治疗依从性的影响:一项整群随机临床试验
该整群随机临床试验在巴西、阿根廷和秘鲁的36家医院、1624例急性缺血性卒中或短暂性脑缺血发作患者中,评估多层面质量改进干预对循证治疗依从性的影响。
要点
- 多层面质量改进干预未显著改善复合依从性评分。
- 全或无复合终点显示干预组依从性显著优于常规护理。
- 干预包括病例管理、提醒、清单、教育材料及定期审计反馈。
核心结论
- 多层面质量改进干预未显著提高急性缺血性卒中或短暂性脑缺血发作患者的复合依从性评分。
- 采用全或无方法分析时,干预改善了循证治疗的依从性。
研究设计与样本
- 研究为2臂整群随机临床试验,评估45家医院和2336例患者合格性后,最终36家医院和1624例患者随机分组。
- 招募自2016年9月12日至2018年2月26日,随访至2018年6月29日,采用意向性治疗原则分析。
主要发现
- 干预组医院10项绩效指标的总体平均复合依从性评分为85.3%(20.1%),对照组为77.8%(18.4%),均值差4.2%(95%CI -3.8%至12.2%)。
临床怎么用
- 对于急性缺血性卒中或短暂性脑缺血发作患者,多层面质量改进干预可提高接受全部适宜循证治疗的比例。
- 复合依从性评分未显著改善,提示干预效果可能因评估方式而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging, especially in low- and middle-income countries. OBJECTIVE: To assess the effect of a multifaceted quality improvement intervention on adherence to evidence-based therapies for care of patients with AIS and TIA. DESIGN, SETTING AND PARTICIPANTS: This 2-arm cluster-randomized clinical trial assessed 45 hospitals and 2336 patients with AIS and TIA for eligibility before randomization. Eligible hospitals were able to provide care for patients with AIS and TIA in Brazil, Argentina, and Peru. Recruitment started September 12, 2016, and ended February 26, 2018; follow-up ended June 29, 2018. Data were analyzed using the intention-to-treat principle. INTERVENTIONS: The multifaceted quality improvement intervention included case management, reminders, a roadmap and checklist for the therapeutic plan, educational materials, and periodic audit and feedback reports to each intervention cluster. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite adherence score for AIS and TIA performance measures. Secondary outcomes included an all-or-none composite end point of performance measures, the individual process measure components of the composite end points, and clinical outcomes at 90 days after admission (stroke recurrence, death, and disability measured by the modified Rankin scale). RESULTS: A total of 36 hospitals and 1624 patients underwent randomization. Nineteen hospitals were randomized to the quality improvement intervention and 17 to routine care. The overall mean (SD) age of patients enrolled in the study was 69.4 (13.5) years, and 913 (56.2%) were men. Overall mean (SD) composite adherence score for the 10 performance measures in the intervention group hospitals compared with control group hospitals was 85.3% (20.1%) vs 77.8% (18.4%) (mean difference, 4.2%; 95% CI, -3.8% to 12.2%). As a secondary end point, 402 of 817 patients (49.2%) at intervention hospitals received all the therapies that they were eligible for vs 203 of 807 (25.2%) in the control hospitals (odds ratio, 2.59; 95% CI, 1.22-5.53; P = .01). CONCLUSIONS AND RELEVANCE: A multifaceted quality improvement intervention did not result in a significant increase in composite adherence score for evidence-based therapies in patients with AIS or TIA. However, when using an all-or-none approach, the intervention resulted in improved adherence to evidence-based therapies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02223273.
引用
- Machline-Carrion MJ, Santucci EV, Damiani LP, et al. Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack: A Cluster Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 31058947. doi:10.1001/jamaneurol.2019.1012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。